Gallbladder Paraganglioma Associated with
18F-DOPA
18F-FDG
68Ga-DOTATATE
Gallbladder
Paraganglioma
SDHD
Journal
Nuclear medicine and molecular imaging
ISSN: 1869-3474
Titre abrégé: Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101530478
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
09
08
2018
revised:
25
10
2018
accepted:
26
11
2018
entrez:
7
5
2019
pubmed:
7
5
2019
medline:
7
5
2019
Statut:
ppublish
Résumé
A 36-year-old male patient initially presented with hypertension, tinnitus, bilateral carotid masses, a right jugular foramen, and a periaortic arch mass with an elevated plasma dopamine level but an otherwise normal biochemical profile. On surveillance MRI 4 years after initial presentation, he was found to have a 2.2-cm T2 hyperintense lesion with arterial enhancement adjacent to the gallbladder, which demonstrated avidity on
Identifiants
pubmed: 31057686
doi: 10.1007/s13139-018-0558-1
pii: 558
pmc: PMC6473097
doi:
Banques de données
ClinicalTrials.gov
['NCT00004847']
Types de publication
Case Reports
Langues
eng
Pagination
144-147Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Déclaration de conflit d'intérêts
Zahraa Abdul Sater, Abhishek Jha, Adel Mandl, Sheila K. Mangelen, Jorge A. Carrasquillo, Alexander Ling, Melissa K. Gonzales, Osorio Lopes Abath Neto, Markku Miettinen, Karen T. Adams, Pavel Nockel, Mustapha El Lakis, and Karel Pacak declare that they have no conflict of interest.This work was supported, in part, by the Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development and was supported, in part, by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute.All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.Informed consent was obtained from the individual participant included in the study.
Références
Eur J Nucl Med. 2000 Mar;27(3):273-82
pubmed: 10774879
Am J Gastroenterol. 2000 Jun;95(6):1607-8
pubmed: 10894624
Yonsei Med J. 2001 Jun;42(3):352-6
pubmed: 11456404
Eur J Nucl Med. 2001 Jul;28(7):836-46
pubmed: 11504080
JAMA. 2004 Aug 25;292(8):943-51
pubmed: 15328326
Clin Nucl Med. 2005 Jan;30(1):23-4
pubmed: 15604962
Arch Pathol Lab Med. 2005 Apr;129(4):523-6
pubmed: 15794679
Int J Oncol. 2006 May;28(5):1249-61
pubmed: 16596242
PLoS One. 2009 Sep 18;4(9):e7094
pubmed: 19763184
J Natl Cancer Inst. 2012 May 2;104(9):700-8
pubmed: 22517990
Nucl Med Commun. 2013 Dec;34(12):1141-9
pubmed: 24128899
Clin Endocrinol (Oxf). 2014 Dec;81(6):789-98
pubmed: 25056984
Prague Med Rep. 2014;115(3-4):145-8
pubmed: 25626334
Clin Cancer Res. 2015 Sep 1;21(17):3888-95
pubmed: 25873086
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1248-57
pubmed: 26637204
Ulus Cerrahi Derg. 2014 Sep 08;31(4):244-6
pubmed: 26668523
J Nucl Med. 2019 Mar;60(3):369-376
pubmed: 30030341
Arch Surg. 1973 Sep;107(3):493
pubmed: 4783050
Arch Surg. 1972 Oct;105(4):637-9
pubmed: 5071170